iScience · 2022 · 22 citations · 44 references
MedicineInfectious DiseasesNeurologyClinical NeuroscienceNeuroinfectious DiseasesNeuropathologyCentral Nervous System InfectionsGlial PathologyNeuroinflammationNeurologic PrognosticationNeuropathology Of InfectionPostinfectious Neurologic SyndromesAssociated Neurological SymptomsLong-term Disease ComplicationsLong-term Neurologic OutcomesLong-term Neurologic SequelaeLong-term Neurological SequelaeNeurofilament ProteinsNeuroinflammatory MarkersSars-cov-2 Infection
Patients with SARS-CoV-2 infection (COVID-19) risk developing long-term neurologic symptoms after infection. Here, we identify biomarkers associated with neurologic sequelae one year after hospitalization for SARS-CoV-2 infection. SARS-CoV-2-positive patients were followed using post-SARS-CoV-2 online questionnaires and virtual visits. Hospitalized adults from the pre-SARS-CoV-2 era served as historical controls. 40% of hospitalized patients develop neurological sequelae in the year after recovery from acute COVID-19 infection. Age, disease severity, and COVID-19 infection itself was associated with additional risk for neurological sequelae in our cohorts. Glial fibrillary astrocytic protein (GFAP) and neurofilament light chain (NF-L) were significantly elevated in SARS-CoV-2 infection. After adjusting for age, sex, and disease severity, GFAP and NF-L remained significantly associated with longer term neurological symptoms in patients with SARS-CoV-2 infection. GFAP and NF-L warrant exploration as biomarkers for long-term neurologic complications after SARS-CoV-2 infection.
44
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Chaolin Huang, Yeming Wang, Xingwang Li et al. · The Lancet · 2020 · 51.8K citations · Full text
Autopsy Findings and Venous Thromboembolism in Patients With COVID-19
Dominic Wichmann, Jan‐Peter Sperhake, Marc Lütgehetmann et al. · Annals of Internal Medicine · 2020 · 2.4K citations · Full text